Jump Financial LLC Has $1.63 Million Stock Position in Guardant Health, Inc. (NASDAQ:GH)

Jump Financial LLC cut its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 98.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 53,404 shares of the company's stock after selling 3,984,190 shares during the quarter. Jump Financial LLC's holdings in Guardant Health were worth $1,631,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in GH. Lord Abbett & CO. LLC bought a new position in Guardant Health in the 3rd quarter worth approximately $15,624,000. Guyasuta Investment Advisors Inc. bought a new position in shares of Guardant Health during the 4th quarter worth about $206,000. Geode Capital Management LLC increased its holdings in shares of Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock worth $64,754,000 after purchasing an additional 29,686 shares during the period. Entropy Technologies LP acquired a new position in shares of Guardant Health during the fourth quarter valued at about $377,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Guardant Health in the fourth quarter valued at about $2,211,000. 92.60% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on GH. The Goldman Sachs Group boosted their price target on Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Raymond James restated an "outperform" rating and issued a $59.00 target price (up from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Mizuho assumed coverage on shares of Guardant Health in a research note on Thursday, April 10th. They set an "outperform" rating and a $55.00 price target on the stock. Guggenheim restated a "buy" rating and issued a $56.00 price objective on shares of Guardant Health in a research note on Monday, February 24th. Finally, Stifel Nicolaus raised their price objective on shares of Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Twenty investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $49.00.

Guardant Health Stock Performance

GH traded up $1.72 during mid-day trading on Thursday, reaching $47.36. The stock had a trading volume of 1,407,753 shares, compared to its average volume of 2,139,860. The stock has a market capitalization of $5.85 billion, a P/E ratio of -13.30 and a beta of 1.45. Guardant Health, Inc. has a 52 week low of $16.77 and a 52 week high of $50.89. The firm's fifty day simple moving average is $43.39 and its two-hundred day simple moving average is $36.82.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. As a group, analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.